Quarterly ResultAug 6, 2026, 07:26 AM
REGENXBIO Q2 Net Income $22.7M, Revenue Jumps to $108M
AI Summary
REGENXBIO Inc. reported a net income of $22.7 million for the second quarter of 2026, a substantial turnaround from a net loss of $70.9 million in the same period last year, driven by a significant increase in total revenues to $108.0 million. Despite the positive quarterly performance, the company recorded a net loss of $67.3 million for the first six months of 2026. The company bolstered its liquidity with a $100.0 million milestone payment from AbbVie and $107.8 million from a public offering in July 2026, extending its cash runway into Q4 2027, though it continues to face an accumulated deficit and regulatory challenges for its product candidates RGX-121 and RGX-111.
Key Highlights
- Reported Q2 2026 net income of $22.7 million, a significant improvement from a $70.9 million net loss in Q2 2025.
- Total revenues for Q2 2026 increased to $108.0 million, up from $21.4 million in Q2 2025.
- Six-month net loss for 2026 was $67.3 million, compared to a $64.8 million net loss in the prior year period.
- Cash, cash equivalents, and marketable securities totaled $105.5 million as of June 30, 2026.
- Received a $100.0 million development milestone payment from AbbVie in July 2026.
- Completed a public offering in July 2026, generating estimated net proceeds of $107.8 million.
- Liquidity is expected to fund operations into the fourth quarter of 2027.
Price Impact
More from RGNX